AU2002227406A1 - Mhc class i associated peptides for prevention and treatment of tuberculosis - Google Patents

Mhc class i associated peptides for prevention and treatment of tuberculosis

Info

Publication number
AU2002227406A1
AU2002227406A1 AU2002227406A AU2740602A AU2002227406A1 AU 2002227406 A1 AU2002227406 A1 AU 2002227406A1 AU 2002227406 A AU2002227406 A AU 2002227406A AU 2740602 A AU2740602 A AU 2740602A AU 2002227406 A1 AU2002227406 A1 AU 2002227406A1
Authority
AU
Australia
Prior art keywords
tuberculosis
prevention
treatment
mhc class
associated peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002227406A
Inventor
David Flyer
Donald F Hunt
Mark M. Ross
Forest M. White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Virginia Patent Foundation
Argonex Pharmaceuticals Inc
Original Assignee
University of Virginia UVA
University of Virginia Patent Foundation
Argonex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA, University of Virginia Patent Foundation, Argonex Pharmaceuticals Inc filed Critical University of Virginia UVA
Publication of AU2002227406A1 publication Critical patent/AU2002227406A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2002227406A 2000-12-13 2001-12-12 Mhc class i associated peptides for prevention and treatment of tuberculosis Abandoned AU2002227406A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25529200P 2000-12-13 2000-12-13
US60/255,292 2000-12-13
US26497801P 2001-01-30 2001-01-30
US60/264,978 2001-01-30
PCT/US2001/048742 WO2002048175A2 (en) 2000-12-13 2001-12-12 Mhc class i associated peptides for prevention and treatment of tuberculosis

Publications (1)

Publication Number Publication Date
AU2002227406A1 true AU2002227406A1 (en) 2002-06-24

Family

ID=26944597

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002227406A Abandoned AU2002227406A1 (en) 2000-12-13 2001-12-12 Mhc class i associated peptides for prevention and treatment of tuberculosis

Country Status (5)

Country Link
US (1) US20020192229A1 (en)
EP (1) EP1353686A4 (en)
AU (1) AU2002227406A1 (en)
CA (1) CA2430896A1 (en)
WO (1) WO2002048175A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE530569T1 (en) * 2005-07-01 2011-11-15 Forsyth Dental In Ry For Children Fa ASSAY FOR THE DETECTION OF TUBERCULOSIS ANTIGENS AND VACCINES
EP2397856B1 (en) 2006-03-14 2013-11-13 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952395A (en) * 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
GB9419553D0 (en) * 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
US5958416A (en) * 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
US6268201B1 (en) * 1998-10-23 2001-07-31 Albert Einstein College Of Medicine Of Yeshiva University IniB, iniA and iniC genes of mycobacteria and methods of use
AU7033400A (en) * 1999-08-30 2001-03-26 Jehad Mikhaiel Charo Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopesof mycobacterial heat shock protein 65
AU2001298049A1 (en) * 2000-10-19 2003-05-19 Epimmune Inc. Hla class i and ii binding peptides and their uses

Also Published As

Publication number Publication date
WO2002048175A2 (en) 2002-06-20
EP1353686A4 (en) 2004-04-07
CA2430896A1 (en) 2002-06-20
WO2002048175A3 (en) 2003-08-21
US20020192229A1 (en) 2002-12-19
EP1353686A2 (en) 2003-10-22

Similar Documents

Publication Publication Date Title
AU2001280455A1 (en) Therapeutic device and system
AU6271401A (en) Drug administering system and administering method
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
AU2001253411A1 (en) Medical dressing assembly and associated method of using the same
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU7907300A (en) Novel combination of loteprednol and antihistamines
AU2002236647A1 (en) Method and device for administering medication and/or placebo
AU2001269314A1 (en) Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
AU4687600A (en) Device and method for the administration of oxygen
AU715620C (en) Therapeutic methods and uses
AU2001294834A1 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
PL362920A1 (en) Therapeutic film forming composition and treatment system
AU2002218502A1 (en) Lactam compounds and medicinal use thereof
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis
AU4014700A (en) Tuberculosis antigens and methods of use therefor
AU5842300A (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss
AU2002227406A1 (en) Mhc class i associated peptides for prevention and treatment of tuberculosis
AU1053501A (en) Polyazanaphthalene compound and medicinal use thereof
AU2000275035A1 (en) Therapeutic and prophylactic drugs of myopia
AU5565401A (en) Materials and methods for the treatment of depression
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases